Cytokinetics Inc vs SAP SE — how do they compare? Cytokinetics Inc trades at $77.39 (market cap $10.63B), while SAP SE trades at $206.8 (market cap $240.81B). The key difference: SAP SE is far larger — about 22.7× Cytokinetics Inc's market cap, and SAP SE pays a 1.4% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | SAP | |
|---|---|---|
Market Cap | $10.63B | $240.81B |
Sector | Technology | Technology |
52-Week High | $87.26 | $280.46 |
52-Week Low | $34.31 | $146.38 |
Enterprise Value | $10.74B | $239.52B |
Dividend Yield | — | 1.4% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →